Datapoint: Idorsia’s Quviviq Approved for Insomnia

The FDA on Monday approved Idorsia Ltd’s Quviviq for the treatment of adults with insomnia. The dual orexin receptor antagonist (DORA) will have to face off against Merck’s Belsomra and Eisai Co.’s Dayvigo, two leading DORAs in the insomnia market basket. Belsomra currently holds covered or better status for 87% of all insured lives under the pharmacy benefit, compared to Dayvigo’s 65%.

SOURCE: MMIT Analytics, as of 1/12/2022

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 8

Datapoint: Humana to Shutter SeniorBridge

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 7

Datapoint: Rigel’s New AML Drug Will Face Off Against Tibsovo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 6

Datapoint: United Projects 9% MA Growth in 2023

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today